Pharmacokinetics of escitalopram in subjects with hepatic impairment

被引：0
|
作者：
Areberg, J [1 ]
Christophersen, JS [1 ]
Poulsen, MN [1 ]
Larsen, F [1 ]
机构：
[1] H Lundbeck & Co AS, Copenhagen, Denmark
来源：
NORDIC JOURNAL OF PSYCHIATRY | 2005年 / 59卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：406 / 406
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment
    Custodio, Joseph M.
    Rhee, Martin
    Shen, Gong
    Ling, Kah Hiing J.
    Kearney, Brian P.
    Ramanathan, Srinivasan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) : 2564 - 2569
  • [42] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [43] A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects
    Krauwinkel, W.
    Noukens, J.
    van Dijk, J.
    Popa, S.
    Ouatas, T.
    de Vries, M.
    Phung, D.
    Gibbons, J.
    Mordenti, J.
    Mateva, L.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) : 268 - 275
  • [44] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [45] Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers
    Zhao, QY
    Iyer, GR
    Verhaeghe, T
    Truyen, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04): : 428 - 436
  • [46] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [47] PHARMACOKINETICS OF BRIVARACETAM IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN MATCHED HEALTHY CONTROLS
    Horsmans, Y.
    Sargentini-Maier, M.
    Stockis, A.
    [J]. EPILEPSIA, 2009, 50 : 113 - 113
  • [48] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    [J]. DIABETOLOGIA, 2002, 45 : A259 - A260
  • [49] Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment
    Puttonen, Jaakko
    Kantele, Sampo
    Ruck, Angela
    Ramela, Meri
    Hakkinen, Sari
    Kivikko, Matti
    Pentikainen, Pertti J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (04): : 445 - 454
  • [50] PHARMACOKINETICS OF CEFPROZIL IN HEALTHY-SUBJECTS AND PATIENTS WITH HEPATIC IMPAIRMENT
    SHYU, WC
    WILBER, RB
    PITTMAN, KA
    GARG, DC
    BARBHAIYA, RH
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04): : 372 - 376
12345